Algorithmes de prise en charge thérapeutique du carcinome épidermoïde cutané invasif. Recommandations de prise en charge du Groupe de Cancérologie Cutanée de la Société Française de Dermatologie

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Annales de Dermatologie et de Vénéréologie - FMC

• Publication date

  2025-11-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.fander.2025.06.006
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial.

  2025cited by this paper
• Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

  2024cited by this paper
• A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6.

  2024cited by this paper
• Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts

  2024cited by this paper
• A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA’s adverse events reporting system

  2024cited by this paper
• European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.

  2023cited by this paper
• Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.

  2023cited by this paper
• 1087MO A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study

  2023cited by this paper
• European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.

  2023cited by this paper
• Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers—Emerging Strategies for Clinical Management

  2023cited by this paper
• Clinical outcomes of high-risk cutaneous squamous cell carcinomas treated with Mohs micrographic surgery alone: an analysis of local recurrence, regional nodal metastases, progression-free survival, and disease-specific death.

  2022cited by this paper
• Majority of cutaneous squamous cell carcinoma recurrences occur within three years after diagnosis: A dual-center retrospective cohort study.

  2022cited by this paper
• 818P Phase II confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6

  2022cited by this paper
• Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

  2022cited by this paper
• Implications of Satellitosis or In-transit Metastasis in Cutaneous Squamous Cell Carcinoma: A Prognostic Omission in Cancer Staging Systems.

  2022cited by this paper
• Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group

  2021cited by this paper
• Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

  2021cited by this paper
• Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial.

  2021cited by this paper
• PD‐1 inhibitors for cutaneous squamous cell carcinoma: A meta‐analysis

  2021cited by this paper
• NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022.

  2021cited by this paper
• British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020 *

  2020cited by this paper
• Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.

  2020cited by this paper
• Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

  2020cited by this paper
• Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women's Hospital alternative staging system for cutaneous squamous cell carcinoma: Implications for clinical practice

  2019cited by this paper
• Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis.

  2018cited by this paper
• Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.

  2018cited by this paper
• Guidelines of care for the management of cutaneous squamous cell carcinoma.

  2018cited by this paper
• Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.

  2018cited by this paper
• The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging

  2017cited by this paper
• PD‐L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis

  2016cited by this paper
• Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma

  2014cited by this paper
• Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system.

  2013cited by this paper
• Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies

  2013cited by this paper
• Sirolimus and secondary skin-cancer prevention in kidney transplantation.

  2012cited by this paper
• Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.

  2011cited by this paper
• Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma.

  2007cited by this paper

• No citing papers are available for this paper.